Tomahawk, WI 07/23/2014 (Basicsmedia) – Puma Biotechnology Inc (NYSE:PBYI) investors have all the reasons to smile as the company’s stocks have tripled overnight. The biotechnology firm has received tremendous success in the form of positive breast cancer drug results.  The company’s stock prices were flying in the extended trading hours.

Breast cancer drug results

Puma Biotechnology Inc (NYSE:PBYI) achieved success in its clinical trial of an experimental drug meant to cure the breast cancer. The results show that the experimental drug is effective in stopping the return attack of breast cancer in women who are in the initial stage of disease.  The experimental drug is named as Neratinib. It enhanced the disease free survival by huge 33%. The trial was conducted on 2.821 women suffering from early-stage HER2-positive breast cancer.

Disease free survival

Many people might be wondering with the term disease free survival. When the women use the drug, they can stay alive with no signs of the illness.  Now when a company has got the success in the clinical trial, it will soon apply for the U.S. regulatory approval. It will seek the approval in early months of 2015. The company management is very excited about the results. However, they were not available to comment more on the matter.

The return of good times

Puma Biotechnology Inc (NYSE:PBYI) had tripled in the extended trading session covering the 43% decline of the year.  If the drug gets the regulatory approval, it will be just the start of profitable time for the company. Neratinib will be used in the patients suffering from early-stage breast cancer. It will stop the growth of tumor promoted by gene called HER2. In the present form of treatment, the patients have to undergo surgery followed by taking Herceptin  of Roche Holding Ltd. (ADR)(OTCMKTS:RHHBY) for a year. If everything goes well, then investors will look to buy the Puma’s stock even after it has tripled overnight.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.